Since its establishment, LBP has been constructing a diversified technology platform, developed a number of core technologies such as sedimentation liquid-based cytology technology, reverse dot blot hybridization PCR preparation technology, real-time PCR preparation technology, FISH probe labeling technology, IHC pathological diagnosis screening and quality control technology and related supporting instrument manufacturing technology, and is one of the most complete and diverse manufacturers in the field of pathological diagnosis in China, which can meet the needs of medical institutions at different levels. LBP has obtained the certificate of National High-Tech Enterprise, and 9 of its core products have won the title of "Guangdong High-Tech Product", as well as many honors such as Guangdong Innovative Enterprise (Pilot) in 2018, Guangdong Pathology Diagnosis Engineering Technology Research Center, etc. The products have passed CE European Authentication, British Standards Institution and the Ministry of Health, Labour, and Welfare of Japan Quality Certification. In the past years, LBP has participated in a number of major national, provincial, and municipal projects under the "863 Program", and has obtained 61 authorized patents, including 17 invention patents, 26 software copyrights, and has more than 500 registered/recorded products, which is increasing continuously. With theindependently-developed reagents and instruments, perfect marketing network and high-quality service system, LBP's products have covered nearly 1,800 medical institutions nationwide.

LBP always takes "Create value for society and customers and realize the goal of employees and enterprises" as its enterprise vision. In the future, LBP will engaged in developing and producing in-vitro diagnostic products of good quality. To fulfill this goal, LBP has newly-built an industrial park of nearly 30,000㎡ in Science City, Guangzhou.